Home/Pipeline/FYB209

FYB209

Not Disclosed

Preclinical/Technical DevelopmentActive

Key Facts

Indication

Not Disclosed

Phase

Preclinical/Technical Development

Status

Active

Company

Formycon

About Formycon

Formycon is a German, publicly traded biosimilar developer with a commercial-stage product and a robust pipeline targeting high-value biologic drugs. The company leverages deep scientific and regulatory expertise to develop biosimilars for markets like the EU and US, aiming to capture significant value in the growing biosimilars market. Its strategy focuses on complex molecules in ophthalmology and immunology, with recent progress including a key settlement for its aflibercept biosimilar in Europe.

View full company profile

Therapeutic Areas

Ophthalmology Immunology

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
SRSD101	Sirius Therapeutics	Phase 1	Active